Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IPA NASDAQ:RZLT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIPAImmunoPrecise Antibodies$2.10+8.5%$2.19$0.43▼$3.25$96.68M0.532.11 million shs1.97 million shsRZLTRezolute$4.91-0.8%$3.84$1.07▼$11.46$472.79M0.542.62 million shs2.79 million shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIPAImmunoPrecise Antibodies0.00%0.00%0.00%0.00%+92.20%RZLTRezolute-4.81%-1.59%+37.12%+58.65%+11.99%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIPAImmunoPrecise Antibodies$2.10+8.5%$2.19$0.43▼$3.25$96.68M0.532.11 million shs1.97 million shsRZLTRezolute$4.91-0.8%$3.84$1.07▼$11.46$472.79M0.542.62 million shs2.79 million shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIPAImmunoPrecise Antibodies0.00%0.00%0.00%0.00%+92.20%RZLTRezolute-4.81%-1.59%+37.12%+58.65%+11.99%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIPAImmunoPrecise Antibodies 0.00N/AN/AN/ARZLTRezolute 2.64Moderate Buy$9.3890.94% UpsideCurrent Analyst Ratings BreakdownLatest RZLT and IPA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/15/2026RZLTRezolute GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$6.00 ➝ $11.006/3/2026RZLTRezolute Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral6/3/2026RZLTRezolute CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform6/3/2026RZLTRezolute Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$11.006/3/2026RZLTRezolute WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$5.00 ➝ $6.006/2/2026RZLTRezolute BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$5.00 ➝ $6.006/2/2026RZLTRezolute Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$10.00 ➝ $14.006/2/2026RZLTRezolute HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.005/14/2026RZLTRezolute Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$4.00 ➝ $10.004/21/2026RZLTRezolute Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 7/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIPAImmunoPrecise Antibodies$17.59M5.50N/AN/A$0.37 per share5.66RZLTRezoluteN/AN/AN/AN/A$1.86 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIPAImmunoPrecise Antibodies-$21.69M-$0.68N/AN/AN/A-122.10%-40.62%-22.19%N/ARZLTRezolute-$74.41M-$0.82N/AN/AN/AN/A-58.82%-54.48%9/16/2026 (Estimated)Latest RZLT and IPA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q3 2026RZLTRezolute-$0.1686-$0.16+$0.0086-$0.16N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthIPAImmunoPrecise AntibodiesN/AN/AN/AN/AN/ARZLTRezoluteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIPAImmunoPrecise Antibodies0.492.081.85RZLTRezoluteN/A15.8415.84Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIPAImmunoPrecise Antibodies6.70%RZLTRezolute82.97%Insider OwnershipCompanyInsider OwnershipIPAImmunoPrecise Antibodies6.83%RZLTRezolute14.78%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIPAImmunoPrecise Antibodies8046.15 million43.00 millionNot OptionableRZLTRezolute4096.29 million82.06 millionOptionableRZLT and IPA HeadlinesRecent News About These CompaniesRezolute, Inc. (NASDAQ:RZLT) Given Average Rating of "Moderate Buy" by BrokeragesJune 30 at 5:03 AM | americanbankingnews.comRezolute (NASDAQ:RZLT) Downgraded by Wall Street Zen to SellJune 30 at 1:06 AM | americanbankingnews.comRezolute Inc.June 29 at 10:23 PM | marketwatch.comFDA Grants Orphan Drug Designation to Rezolute's Ersodetug (RZ358) for the Treatment of Hypoglycemia Due to Tumor HyperinsulinismJune 25, 2026 | stockhouse.comRezolute (NASDAQ:RZLT) Rating Increased to Hold at Wall Street ZenJune 22, 2026 | americanbankingnews.comRezolute Highlights Results Presented from Natural History Outcomes Studies and its Ersodetug Clinical Program in Hyperinsulinism at Annual Meeting of the Endocrine SocietyJune 17, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Rezolute (RZLT) and Vericel (VCEL)June 12, 2026 | theglobeandmail.comPositive Signs As Multiple Insiders Buy Rezolute StockJune 10, 2026 | finance.yahoo.comRZLT Stock on the Move: What Sparks the 38% Jump in the Past Week?June 4, 2026 | zacks.comRezolute, Inc. Announces Four Presentations at the 2026 Annual Meeting of the Endocrine Society on Ersodetug for Congenital HyperinsulinismJune 4, 2026 | quiverquant.comQRezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine SocietyJune 4, 2026 | globenewswire.comAnalysts Are Bullish on These Healthcare Stocks: Rezolute (RZLT), Relay Therapeutics (RLAY)June 3, 2026 | theglobeandmail.comRezolute upgraded at Citizens after late-stage trial data for lead assetJune 3, 2026 | seekingalpha.comRezolute rises after late-stage trial updateJune 3, 2026 | msn.comRezolute Highlights Strong Early Response Trends In Rare Hypoglycemia Disease StudyJune 2, 2026 | benzinga.comRezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor HyperinsulinismJune 2, 2026 | globenewswire.comRezolute Reports Third Quarter Fiscal 2026 Financial Results and Provides Business UpdateMay 12, 2026 | globenewswire.comRezolute to Participate in Upcoming Investor ConferencesMay 11, 2026 | globenewswire.comRezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism at the Pediatric Endocrine Society ...May 1, 2026 | markets.businessinsider.comRezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism at the Pediatric Endocrine Society Annual MeetingMay 1, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRZLT and IPA Company DescriptionsImmunoPrecise Antibodies NASDAQ:IPAImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada.Rezolute NASDAQ:RZLT$4.91 -0.04 (-0.81%) Closing price 04:00 PM EasternExtended Trading$4.88 -0.03 (-0.61%) As of 06:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon SanDisk’s Volatility May Be Telling Bulls What They Want to Hear Shorting the Grid: Bloom Energy’s $25B AI Power Play SMRs Spark a Chain Reaction for Nano Nuclear 3 Dividend ETFs Built for Stability in a Volatile Market Agility Robotics’ SPAC Deal Opens a Rare Door Into Humanoid AI Netflix Stock Is Near 2021 Levels, and Bulls See 4 Reasons to Care General Mills Is a 5-Star Turnaround Play for Buy and Hold Investors Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
